法國里爾大學Adriaenssens等的研究表明,，以神經(jīng)生長因子(NGF,，神經(jīng)營養(yǎng)因子之一)為靶點,，可抑制乳腺癌細胞的增殖、存活和轉(zhuǎn)移,，故NGF是乳腺癌的潛在治療靶點《癌癥研究》（Cancer Research）,。
研究者對一系列活檢組織的分析表明，NGF在絕大多數(shù)人類乳腺腫瘤中都有廣泛表達,，抗NGF免疫反應(yīng)主要集中在上皮性癌細胞。此外,，在異種移植人類乳腺癌細胞的免疫缺陷鼠中也觀察到,，抗NGF抗體或抗NGF的小干擾RNA治療可抑制腫瘤的生長和轉(zhuǎn)移。這些直接以NGF為靶點的治療在引起細胞增殖下降的同時,，還可促進細胞凋亡和抑制腫瘤血管生成,。
乳腺癌靶向治療是分子水平的治療方式，目前已有多種靶向藥物應(yīng)用于臨床,，神經(jīng)生長因子在乳腺腫瘤的生長和轉(zhuǎn)移過程中有其特定作用,，有望成為新的靶向治療靶點。（來源：中國醫(yī)學論壇報 張瑾）
生物谷推薦原始出處：
（Cancer Research）,，68, 346-351, January 15, 2008,，Eric Adriaenssens, Hubert Hondermarck
Nerve Growth Factor Is a Potential Therapeutic Target in Breast Cancer
Eric Adriaenssens1, Elsa Vanhecke1, Pasquine Saule3, Alexandra Mougel3, Adeline Page2, Rodrigue Romon1, Victor Nurcombe4, Xuefen Le Bourhis1 and Hubert Hondermarck1
1 INSERM U908, Institut National de la Sante et de la Recherche Medicale, "Growth factor signaling in breast cancer cells. Functional Proteomics", IFR-147 and 2 Mass Spectrometry Facility, IFR-147, University Lille 1, 3 Centre National de la Recherche Scientifique UMR8527, Institute of Biology, Lille, France; and 4 Institute of Molecular and Cell Biology, Singapore, Singapore
Requests for reprints: Hubert Hondermarck, INSERM U908, Institut National de la Sante et de la Recherche Medicale, University Lille 1, Batiment SN3, 59655 Villeneuve d'Ascq, Lille, France. Phone: 33-320-43-40-97; E-mail: [email protected] .
We show here that nerve growth factor (NGF), the prototypic neurotrophin, can be targeted in breast cancer to inhibit tumor cell proliferation, survival, and metastasis. Analysis of a series of biopsies revealed widespread expression of NGF in the majority of human breast tumors, with anti-NGF immunoreactivity concentrated in the epithelial cancer cells. Moreover, immunodeficient mice xenografted with human breast cancer cells and treated with either anti-NGF antibodies or small interfering RNA against NGF displayed inhibited tumor growth and metastasis. Such treatments directed against NGF induced a decrease in cell proliferation with a concomitant increase in apoptosis of breast cancer cells and an inhibition of tumor angiogenesis. Together, these data indicate that targeting NGF in breast cancer may have therapeutic ramifications. [Cancer Res 2008;68(2):346–51]
